Skye Bioscience, Inc. reports clinical-stage biotechnology developments focused on metabolic health disorders, obesity and overweight. The company's lead program, nimacimab, is a peripherally restricted monoclonal antibody inhibitor of the CB1 receptor being evaluated in the CBeyond Phase 2a program, including monotherapy and combination work with GLP-1 or other incretin-based therapies.
Recurring updates cover clinical data from CBeyond, higher-dose safety and pharmacokinetic work, regulatory feedback on follow-on trial design, manufacturing and formulation activities, scientific conference presentations, financial results and corporate outlooks. Skye also discusses its broader strategy of developing molecules that modulate G-protein-coupled receptors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Skye Bioscience (OTCQB: SKYE) announced the completion of SBI-100 Ophthalmic Emulsion production for its Phase 1 clinical trial, which focuses on treating glaucoma. The final product is expected to be clinically available in October, pending quality testing results. Clinical site initiation will occur in mid-October, followed by patient dosing starting in November. SBI-100 OE aims to effectively lower intraocular pressure (IOP) using a novel synthetic cannabinoid formulation, potentially offering a new treatment class for glaucoma, a leading cause of irreversible blindness.
Skye Bioscience, Inc. (OTCQB: SKYE) announced the filing of its definitive proxy statement ahead of a special meeting on September 30, 2022. This meeting will address a proposed business combination with Emerald Health Therapeutics, Inc. Stockholders as of August 29, 2022, will receive voting materials via mail or email. CEO Punit Dhillon expressed gratitude for Emerald's support and emphasized the importance of stockholder voting to secure valuable resources for their business plan. The definitive proxy statement is available for viewing online.